Collegium Pharmaceutical, Inc. provided revenue guidance for the full year 2021. For the year, the company expected Xtampza ER Revenues to be in the range of $140.0 million to $150.0 million up from the previously provided range of $155.0 million to $165.0 million. Nucynta Franchise Revenues to be in the range of $195.0 million to $205.0 million up from the previously provided range of $185.0 million to $195.0 million.